Comparison 2. RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Global state: 1. Relapse (any reason)	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 long term	1	63	Risk Ratio (M‐H, Random, 95% CI)	2.13 [0.84, 5.43]
2 Global state: 2. Needing use of benzodiazepine or sedative drugs	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 long term	1	369	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.68, 1.47]
3 Service utilisation: 1. Hospitalisation	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 long term	1	369	Risk Ratio (M‐H, Random, 95% CI)	0.87 [0.68, 1.10]
4 Service utilisation: 2. Outpatient care ‐ number of outpatient visits (skewed data)			Other data	No numeric data
4.1 long term			Other data	No numeric data
5 Not receiving allocated study medication	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 long term	1	382	Risk Ratio (M‐H, Random, 95% CI)	0.29 [0.06, 1.37]
6 Leaving the study early: 1. Any reason	2	467	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.98, 1.57]
6.1 long term	2	467	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.98, 1.57]
7 Leaving the study early: 2. Specific	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 insufficient response ‐ long term	1	382	Risk Ratio (M‐H, Random, 95% CI)	0.61 [0.15, 2.50]
7.2 withdrawn consent ‐ long term	1	382	Risk Ratio (M‐H, Random, 95% CI)	1.41 [0.86, 2.31]
8 Adverse events: 1. General: a. Death	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 long term	1	382	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.14, 7.10]
9 Adverse events: 2. Specific	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 anxiety ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	1.40 [0.42, 4.60]
9.2 diabetes mellitus ‐ long term	1	369	Risk Ratio (M‐H, Random, 95% CI)	1.70 [0.73, 3.96]
9.3 dizziness ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	1.49 [0.53, 4.19]
9.4 fatigue/somnolence ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	2.05 [0.78, 5.40]
9.5 gastrointestinal ‐ long term	1	369	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.95, 1.28]
9.6 general disorders and administration site conditions ‐ long term	1	369	Risk Ratio (M‐H, Random, 95% CI)	1.31 [1.02, 1.69]
9.7 headache ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	2.80 [1.12, 7.00]
9.8 insomnia ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	1.73 [0.77, 3.91]
9.9 nausea/ vomiting ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	1.86 [0.50, 6.97]
9.10 prolactin related ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	10.27 [0.59, 180.05]
9.11 weight increase ‐ long term	1	85	Risk Ratio (M‐H, Random, 95% CI)	1.33 [0.56, 3.17]
10 Adverse events: Nervous system disorders (inc. EPS)	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
10.1 long term	1	369	Risk Ratio (M‐H, Random, 95% CI)	1.34 [1.13, 1.58]